Abstract
Risk Factors for Poor Treatment Outcomes in Patients With MDR-TB and XDR-TB in China: Retrospective Multicenter Investigation
Highlights
Despite global efforts to control tuberculosis (TB), the global burden of TB remains enormous
Patient Demographics Among 1662 HIV-seronegative TB cases which were culturepositive for M. tuberculosis complex and had positive sputumsmear microscopy results, 965 cases (58.1%) were drug resistant (DR), and 586 cases (35.3%) were classified as having multidrug resistant tuberculosis (MDR-TB), accounting for 60.7% of DR-TB. 169 cases (10.2%) were XDR-TB, accounting for 17.5% of DR-TB, 28.8% of MDR-TB
The data from five large-scale Tuberculosis Specialized Hospitals in China showed that 35.3% of cases (586/1662) were classified as having MDR-TB, and 28.8% of MDR-TB was XDR-TB
Summary
Despite global efforts to control tuberculosis (TB), the global burden of TB remains enormous. There were estimated to be 8.7 million incident cases of TB in 2011. XDR-TB is defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone, and 1 of 3 injectable second-line drugs (amikacin, kanamycin, or capreomycin). There is little information available on risk factors for poor outcomes in patients with MDR- and XDR-TB in China. Methodology/Principal Findings: We retrospectively analyzed the clinical records of HIV-negative TB Patients with culture-proven MDR- or XDR-TB who were registered from July 2006 to June 2011 at five large-scale Tuberculosis Specialized Hospitals in China. 240 patients (40.95%) had treatment success, and 346 (59.05%) had poor treatment outcomes. Conclusions/Significance: The patients with MDR-TB and XDR-TB have poor treatment outcomes in China.The presence of extensive drug resistance, low BMI, hypoalbuminemia, comorbidity, cavitary disease and previous antiTB treatment are independent prognostic factors for poor outcome in patients with MDR-TB
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
